OBJECTIVES Evaluation of 30-day outcomes after transcatheter aortic valve replacement (TAVR) with the novel balloon-expandable SAPIEN 3 (S3) transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) emphasizing the updated Valve Academic Research Consortium (VARC-2) criteria.
T ranscatheter aortic valve replacement (TAVR) has rapidly evolved from a novel technology to the preferred treatment for patients with severe symptomatic aortic stenosis who cannot undergo conventional surgical aortic valve replacement (1) and has been shown to be noninferior in high-risk patients (2) . Large clinical registries have consistently reported excellent outcomes (3) (4) (5) and decreased complication rates (6) .
Although, in part, this decrease may be attributable to increasing operator experience, the evolution of devices or requiring valve-in-valve procedures due to degenerated bioprostheses were excluded from the analysis. Therefore, the final study population consisted of 250 patients. All cases were discussed by the multidisciplinary heart team, and consensus was achieved regarding the therapeutic strategy. TAVR was performed in a hybrid operating suite with patients under general anesthesia or conscious sedation. All patients provided written informed consent for the procedure.
ECHOCARDIOGRAPHY AND MULTISLICE COMPUTED TOMOGRAPHY DATA ANALYSIS. Transthoracic echocardiography was performed before TAVR, before discharge, and at the 30-day follow-up visit. Left ventricular ejection fraction, mean transvalvular gradient, and paravalvular regurgitation were determined. Discharge echocardiographic data were available for 242 patients, and 30-day echocardiographic follow-up was available in 185 patients.
Multislice computed tomography (MSCT) was performed as part of the standard pre-procedural screening protocol. Aortic annulus measurements were assessed in multiple plane reconstructions according to the guidelines of the Society of Cardiovascular Computed Tomography (14) . In short, the area and perimeter of the virtual aortic annulus were obtained by direct planimetry. The minimal and maximal diameter were determined, and the effective diameter was calculated as the sum of the minimal and maximal diameter divided by 2. Calcification of the valvular apparatus was assessed at the height of the aortic cusps, annulus, and the left ventricular outflow tract and visually graded as none, mild, moderate, and severe. Dedicated U.S. Food and Drug Administration-approved software (OsiriX MD 3.9.4, Pixmeo, Switzerland) was used.
PROSTHESIS SIZE SELECTION AND PROCEDURE.
The technical features of the S3 THV have been described elsewhere (7, 11) . The device is available in Table 2 . MSCT measurements of the aortic annulus are presented in Table 3 . Measurements were evaluated for 248 patients because 1 patient did not undergo MSCT due to renal failure and 1 patient had not previously undergone MSCT. In-hospital outcome and complications are given in Table 5 . Values are n (%), mean AE SD, or median (interquartile range). *Balloon with the recommended volume included with the delivery system and transcatheter heart valve (THV) (i.e., 20-mm balloon for 23-mm THV, 23-mm for 26-mm THV, and 25-mm for 29 mm-THV). †Post-dilation was performed using the delivery system's balloon and adding w1 to 2 ml to the recommended filling volume at the operator's discretion.
ECMO ¼ extracorporeal membrane oxygenation. Husser et al.
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VARC-2-DEFINED EARLY SAFETY AT 30 DAYS.
Follow-up at 30 days was complete in 249 patients.
One patient was lost to follow-up due to inability to contact. The 30-day event-free rate was 90.0%
(225 of 250), with the composite early safety endpoint observed in 10.0% (25 of 250) ( Table 5) . New York Heart Association (NYHA) functional class at baseline and discharge for 250 patients with complete follow-up at 30 days. 
DISCUSSION
We report our initial experience of in-hospital and 30-day event rates according to VARC-2 in a mediumsized patient population using a novel balloonexpandable THV. We found excellent outcomes using the S3 THV with very low mortality and high device success rates. With the final PARTNER II S3 results pending, our study may be of interest to clinicians using this novel device. STROKE. New cerebrovascular events after TAVR are frequent but are silent in most cases. The incidence of 30-day clinically apparent major or disabling stroke is in the range of w2% to 4% (25-28) and seems to be independent of valve type and access (27) . We observed a rate of disabling stroke of 1.6%, comparing favorably with these previous data being at the lower limit of the expected. Other groups, treating patients with a transfemoral S3 THV, have reported similar stroke rates ranging from 0 to 2% (8, (10) (11) (12) .
NEW PERMANENT PACEMAKER IMPLANTATIONS.
The incidence of new permanent pacemaker implantations after TAVR using balloon-expandable valves ranges between 5% and 12% (1, 29, 30) . 
CONCLUSIONS
We report our first experience using a novel balloonexpandable THV redesigned to minimize residual paravalvular leakage and with low-profile sheaths. hengstenberg@gmail.com.
